Basilea Pharmaceutica (FRA:PK5) General and Admin. Expense: €38.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PK5 Basilea Pharmaceutica Ltd FRA:PK5
61 GF Score
Price €59.10
GF Value €62.49
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica General and Admin. Expense?

Basilea Pharmaceutica FRA:PK5 -0.34% 61 General and Admin. Expense is €38.1 Mil as of Dec. 2025. GuruFocus rates FRA:PK5 with a GF Score™ of 61/100 and a GF Value™ of €62.49 (Fairly Valued). The stock has 4 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Basilea Pharmaceutica's General and Admin. Expense for the six months ended in Dec. 2025 was €19.5 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €38.1 Mil.

Basilea Pharmaceutica General and Admin. Expense Related Terms

Basilea Pharmaceutica General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica General and Admin. Expense Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.56 31.23 35.82 33.79 38.17

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.28 15.92 17.37 18.56 19.52
FRA:PK5
61GF Score
Basilea Pharmaceutica Ltd FRA:PK5
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €38.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €38.1 Mil mean?
Basilea Pharmaceutica (FRA:PK5) has a General and Admin. Expense of €38.1 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's General and Admin. Expense too high?
Basilea Pharmaceutica's current General and Admin. Expense is €38.1 Mil. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's General and Admin. Expense compare to VRTX and REGN?
Basilea Pharmaceutica's General and Admin. Expense of €38.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current General and Admin. Expense is €38.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (FRA:PK5) is currently considered Fairly Valued. The stock's GF Value™ is €62.49, compared to a current price of €59.10 — trading 5.4% below its estimated fair value. The current General and Admin. Expense is €38.1 Mil. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Basilea Pharmaceutica (FRA:PK5), the current General and Admin. Expense is €38.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (FRA:PK5) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of €59.10 is trading 5.4% below its estimated GF Value™ of €62.49. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for FRA:PK5:

  • General and Admin. Expense: €38.1 Mil
  • GF Value™: €62.49 vs. price of €59.10 (5.4% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the FRA:PK5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for FRA:PK5

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€59.10
Price
€62.49
GF Value